Real-world (RW) outcomes of second-line (2L) small cell lung cancer (SCLC) patients treated with lurbinectedin

被引：4
|
作者：
Estrin, A. [1 ]
Wang, X. [2 ]
Boccuti, A. [3 ]
Prince, P. [1 ]
Gautam, N. [1 ]
Rengarajan, B. [3 ]
Li, W. [2 ]
Lu, T. [3 ]
Cao, Y. [2 ]
Naveh, N. [2 ]
D'Agostino, R. [4 ]
Ben-Joseph, R. [3 ]
Ganti, A. K. [5 ]
机构：
[1] Aetion Inc, Sci, New York, NY USA
[2] Jazz Pharmaceut, Med Affairs, Philadelphia, PA USA
[3] Jazz Pharmaceut, Med Affairs, Palo Alto, CA USA
[4] Wake Forest Univ Sch Med, Biostat & Data Sci, Winston Salem, NC USA
[5] Univ Nebraska Med Ctr, VA Nebraska Western Iowa Hlth Care Syst, Nebraska Med Ctr, Omaha, NE USA
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.1633
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1539P
引用
收藏
页码：S1250 / S1250
页数：1
相关论文
共 50 条
  • [41] Outcomes of second-line chemotherapy in patients with relapsed extensive small cell lung cancer
    Froeschl, Sandra
    Nicholas, Garth
    Gallant, Victor
    Laurie, Scott A.
    JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (02) : 163 - 169
  • [42] Real-world Safety and Dosing of Lurbinectedin-Treated Patients with Small Cell Lung Cancer: Jazz EMERGE 402 Preliminary Analysis
    Halmos, B.
    Lammers, P.
    Patel, M.
    Shapira, I.
    Shunyakov, L.
    Slater, D.
    Labbe, C.
    Naveh, N.
    Boccuti, A.
    Hanvesakul, R.
    Li, W.
    Rengarajan, B.
    Badin, F.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S381 - S381
  • [43] Real-world outcomes and patient (pt) characteristics for the second-line (2L) treatment of gastric, esophageal, or gastroesophageal junction (GEJ) adenocarcinoma (EGAC).
    Barzi, Afsaneh
    Hess, Lisa M.
    Zhu, Yajun
    Liepa, Astra M.
    Fang, Yun
    Kuder, Craig Heath
    Beyre, Julie
    Chao, Joseph
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [44] Prognostic factors for response and survival of second-line chemotherapy in patients with relapsed small cell lung cancer (SCLC)
    Kim, Y.
    Goto, K.
    Yoh, K.
    Niho, S.
    Ohmatsu, H.
    Kubota, K.
    Saijo, N.
    Nishiwaki, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [45] Real-World Use of Lurbinectedin in Patients with Small Cell Lung Cancer: Jazz EMERGE 402 Updated Analysis
    Halmos, Balazs
    Lammers, Philip
    Pate, Mehul
    Shapira, Juliana
    Shunyakov, Leonid
    Slater, Dennis
    Labbe, Catherine
    Naveh, Navit
    Boccuti, Anne
    Hanvesaku, Raj
    Li, Wenyan
    Rengarajan, Badri
    Badin, Firas
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E52 - E52
  • [46] EMERGE 402: Preliminary Real-world Characteristics and Safety of Lurbinectedin in Patients With Small-cell Lung Cancer
    Bushunow, P.
    Dakhil, S.
    Lammers, P.
    Naveh, N.
    Boccuti, A.
    Hanvesakul, R.
    Li, W.
    Migas, J.
    Slater, D.
    Badin, F.
    Halmos, B.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S145 - S146
  • [47] Real-world (RW) use patterns, effectiveness, and tolerability of sacituzumab govitecan (SG) for second-line (2L) and later treatment of metastatic triple-negative breast cancer (mTNBC)
    Kalinsky, K.
    Spring, L.
    Yam, C.
    Ntalla, I.
    Stwalley, B.
    Sjekloca, N.
    Lai, C.
    Kaushiva, A.
    Taylor, A. J.
    Nanda, R.
    ANNALS OF ONCOLOGY, 2023, 34 : S345 - S346
  • [48] REAL-WORLD OUTCOMES IN THIRD-LINE AND BEYOND (3L+) SMALL-CELL LUNG CANCER (SCLC): A SYSTEMATIC LITERATURE REVIEW (SLR)
    Dirnberger, F.
    Appiah, K.
    Mayer, B.
    Rizzo, M.
    Suri, G.
    VALUE IN HEALTH, 2023, 26 (12) : S32 - S32
  • [49] Efficacy and safety of lurbinectedin in Chinese patients with extensive-stage small cell lung cancer (ES-SCLC): A multicenter, retrospective real-world study
    Xiang, Y.
    Tang, Y.
    Luan, T.
    Mengchen, L.
    Shi, W.
    Chin, A. G. W.
    Feng, X.
    Wang, F.
    Sun, X. W.
    Bao, Z.
    Zhou, J.
    Zhao, J.
    Wu, H.
    Fu, D.
    ANNALS OF ONCOLOGY, 2024, 35 : S1666 - S1667
  • [50] Second-line chemotherapy with cyclophosphamide, doxorubicin and vincristine (CAV) in patients with small cell lung cancer (SCLC) initially treated with platinum and etoposide.
    Moreau, S
    Labrune, S
    Gozy, M
    Giraud, V
    Le Guillou, F
    Blivet, S
    Chinet, T
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 701S - 701S
12345